Corbus Pharmaceuticals Holdings, Inc. (CRBP)Healthcare | Biotechnology | Norwood, United States | NasdaqCM
4.52 USD
+0.19
(4.388%)
⇧
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 4.58 +0.06 (1.409%) ⇧ (Oct. 16, 2026, 4:19 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 3:07 a.m. EDT
The investment case for Corbus Pharmaceuticals is currently broken by a perfect storm of deteriorating fundamentals and aggressive short-term selling pressure. The company is bleeding cash, with operating cash flow at -$86 million and free cash flow at -$49 million, while posting negative returns on both assets and equity. This financial distress is compounded by a catastrophic multi-year price trajectory; the stock has lost 94.59% of its value over the last nine years, with the most recent annual performance showing a decline. Despite a 'strong buy' analyst recommendation based on potential future upside, the market has already priced in a lack of near-term viability, driving the price down to near book value. The options market confirms this pessimism, with traders loading up on cheap put insurance rather than betting on a rally. With no dividend to provide income and a balance sheet that cannot sustain the current burn rate indefinitely, the risk-reward profile is skewed heavily against the buyer. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.301565 |
| AutoETS | 0.302955 |
| AutoARIMA | 0.304262 |
| AutoTheta | 0.335692 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 44.17 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.240 |
| Excess Kurtosis | -1.04 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.171 |
| Market Cap | 87,422,640 |
| Forward P/E | -0.82 |
| Beta | 2.63 |
| Website | https://www.corbuspharma.com |
As of Oct. 10, 2026, 3:07 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by massive open interest in deep out-of-the-money puts ($10.2k at $7.50 strike) compared to negligible call volume. While there is some speculative call activity at $15-$20 strikes, the overwhelming capital flow is defensive, suggesting a belief that the stock will struggle to recover from its recent lows without significant catalysts.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7758799 |
| Address1 | 500 River Ridge Drive |
| All Time High | 323.4 |
| All Time Low | 2.11 |
| Ask | 5.19 |
| Ask Size | 1 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 987,970 |
| Average Daily Volume3 Month | 811,825 |
| Average Volume | 811,825 |
| Average Volume10Days | 987,970 |
| Beta | 2.632 |
| Bid | 4.55 |
| Bid Size | 1 |
| Board Risk | 3 |
| Book Value | 5.476 |
| City | Norwood |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.52 |
| Current Ratio | 5.714 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 4.72 |
| Day Low | 4.2201 |
| Debt To Equity | 4.171 |
| Display Name | Corbus Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,794,832,200 |
| Earnings Timestamp Start | 1,794,832,200 |
| Ebitda | -106,678,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.281 |
| Enterprise Value | -29,929,202 |
| Eps Current Year | -5.434 |
| Eps Forward | -5.51333 |
| Eps Trailing Twelve Months | -6.11 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.4242 |
| Fifty Day Average Change | -3.9042 |
| Fifty Day Average Change Percent | -0.46345055 |
| Fifty Two Week Change Percent | -77.58799 |
| Fifty Two Week High | 20.56 |
| Fifty Two Week High Change | -16.039999 |
| Fifty Two Week High Change Percent | -0.7801556 |
| Fifty Two Week Low | 4.2201 |
| Fifty Two Week Low Change | 0.29990005 |
| Fifty Two Week Low Change Percent | 0.07106468 |
| Fifty Two Week Range | 4.2201 - 20.56 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,414,416,600,000 |
| Float Shares | 13,248,205 |
| Forward Eps | -5.51333 |
| Forward P E | -0.8198312 |
| Free Cashflow | -49,618,124 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 36 |
| Fullday Change | 0.25370026 |
| Fullday Change Percent | 5.8591285 |
| Fullday Price | 4.5837 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -90,260,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.012359999 |
| Held Percent Institutions | 0.83761 |
| Implied Shares Outstanding | 19,341,293 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,676,332,800 |
| Last Split Factor | 1:30 |
| Long Business Summary | Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts. |
| Long Name | Corbus Pharmaceuticals Holdings, Inc. |
| Market | us_market |
| Market Cap | 87,422,640 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_254045988 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -101,903,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 140,417,787 |
| Number Of Analyst Opinions | 10 |
| Open | 4.35 |
| Operating Cashflow | -86,668,000 |
| Operating Margins | 0.0 |
| Overall Risk | 5 |
| Phone | 617 963 0100 |
| Post Market Change | 0.0637002 |
| Post Market Change Percent | 1.4092964 |
| Post Market Price | 4.5837 |
| Post Market Time | 1,792,181,957 |
| Previous Close | 4.33 |
| Price Eps Current Year | -0.83179975 |
| Price Hint | 4 |
| Price To Book | 0.82542 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.56 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.1 |
| Region | US |
| Regular Market Change | 0.19000006 |
| Regular Market Change Percent | 4.3879924 |
| Regular Market Day High | 4.72 |
| Regular Market Day Low | 4.2201 |
| Regular Market Day Range | 4.2201 - 4.72 |
| Regular Market Open | 4.35 |
| Regular Market Previous Close | 4.33 |
| Regular Market Price | 4.52 |
| Regular Market Time | 1,792,180,802 |
| Regular Market Volume | 1,064,847 |
| Return On Assets | -0.52999 |
| Return On Equity | -0.9558 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 19,341,293 |
| Shares Percent Shares Out | 0.158 |
| Shares Short | 3,054,964 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 2,245,998 |
| Short Name | Corbus Pharmaceuticals Holdings |
| Short Percent Of Float | 0.1808 |
| Short Ratio | 2.35 |
| Source Interval | 15 |
| State | MA |
| Symbol | CRBP |
| Target High Price | 48.0 |
| Target Low Price | 17.25 |
| Target Mean Price | 34.025 |
| Target Median Price | 34.0 |
| Total Cash | 117,941,000 |
| Total Cash Per Share | 6.098 |
| Total Debt | 4,264,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -6.11 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.832825 |
| Two Hundred Day Average Change | -4.3128247 |
| Two Hundred Day Average Change Percent | -0.48827243 |
| Type Disp | Equity |
| Volume | 1,064,847 |
| Website | https://www.corbuspharma.com |
| Zip | 2,062 |